AXON Presented Its Tau Vaccine in Two Presentations at 14Th AAT Conference
AXON Neuroscience presented two topics from its disease modifying AD program at the 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy. In the first presentation Axon introduced the endpoints and the design of the phase II clinical trial with the first active tau vaccine, AADvac1, in patients with mild Alzheimer’s disease. In the second presentation, AXON presented the immunology profile of AADvac1 from the successful Phase I study which was performed in Austria with 30 patients at 4 clinical sites
AADVAC1 PHASE II CLINICAL STUDY
AXON’s active vaccine AADvac1 is intended to be a disease-modifying drug for Alzheimer’s disease. AXON has previously demonstrated positive results of preclinical research with a significant reduction of tau pathology in transgenic animal models and improvement of their survival and neurobehavioral symptoms. The Phase I study in humans has confirmed that AADvac1 is safe and well tolerated. It induced a robust immune response and the cognition of the patients remained on average stable for the whole duration of the Phase I study.
At the Springfield Symposium, AXON’s Medical Director, Matej Ondrus, highlighted the above mentioned results as an excellent starting point for designing the Phase II clinical study. This study aims to confirm the proof-of-concept in a larger patient population. He presented the study design powered for both the primary endpoints of safety and tolerability and a secondary endpoint of efficacy in mild Alzheimer’s disease patients. The study will assess 185 randomized subjects in 7 countries of Europe with an overall study duration of 24 months.
After the presentation, Matej Ondrus added: “We are excited to present the official start of the Phase II study with the first patient already screened on March 9 th , 2016. ”
AADVAC1 IMMUNOLOGY PROFILE
Norbert Zilka, Chief Science Officer of AXON Neuroscience presented results on the excellent immunological profile of the AADvac1 vaccine in Phase I clinical trial. The study demonstrated that more than. 80% of the vaccine responders generated titers higher than 1:10,000. AADvac1 is the first vaccine against AD that was able to overcome the low antibody responsiveness typically seen in elderly people.
AXON Neuroscience is a biotech company with a mission to deliver disease-modifying treatment for patients suffering from Alzheimer's disease and other tauopathies.
+421 902 161 362
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
PA-MEET-GROUP19.10.2017 23:00 | pressemeddelelse
The Meet Group Announces Closing of Lovoo Acquisition
CA-EDGEWATER-NETWORKS19.10.2017 22:02 | pressemeddelelse
Edgewater Networks Announces SD-WAN Optimized for BroadSoft Platforms
BUSINESS-WIRE19.10.2017 21:22 | pressemeddelelse
Business Wire Receives Type 2 SOC 2 Attestation Engagement Report Related to Security
BUSINESS-WIRE19.10.2017 21:05 | pressemeddelelse
Business Wire Receives Type 2 SOC 2 Attestation Engagement Report Related to Security of ‘BW Connect,’ Its Order-Entry Interface, and ‘HQ,’ Its Web-Hosting Services
PHARNEXT19.10.2017 19:33 | pressemeddelelse
Pharnext: First-Half 2017
NC-TIEC19.10.2017 19:00 | pressemeddelelse
Tickets Now on Sale for FEI World Equestrian Games Tryon 2018, North Carolina, USA, on September 11-23, 2018
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum